Inhibition of glutaminolysis alone and in combination with HDAC inhibitor has anti-myeloma therapeutic effects

Abstract

Aim: This study aimed to investigate drug candidates and their efficacy in treating refractory multiple myeloma (MM) despite significant therapeutic advances and the introduction of novel agents. Our study focused on how myeloma cells mediate the metabolic pathways essential for survival. Therefore, we examined the role of glutaminolysis in this process.

Methods: We investigated the role of glutaminolysis in myeloma cell growth. In addition, we analyzed the ability of CB-839 (telaglenastat), a glutaminase (GLS) inhibitor, to suppress myeloma cell proliferation and enhance the sensitivity to histone deacetylase (HDAC) inhibitors.

Results: Glutamate deprivation significantly reduced MM cell proliferation. We observed an upregulation of GLS1 expression in MM cell lines compared to that in normal controls. CB-839 inhibits MM cell proliferation in a dose-dependent manner, resulting in enhanced cytotoxicity. Additionally, intracellular α-ketoglutarate and nicotinamide adenine dinucleotide phosphate levels decreased after CB-839 administration. Combining panobinostat with CB-839 resulted in enhanced cytotoxicity and increased caspase 3/7 activity. Cells transfected with GLS shRNA exhibited reduced cell viability and elevated sub-G1 phase according to cell cycle analysis results. Compared to control cells, these cells also showed increased sensitivity to panobinostat.

Conclusion: Glutaminolysis contributes to the viability of MM cells, and the GLS inhibitor CB-839 has been proven to be an effective treatment for enhancing the cytotoxic effect of HDAC inhibition. These results are clinically relevant and suggest that CB-839 is a potential therapeutic candidate for patients with MM.

Keywords

Multiple myeloma / glutaminolysis / GLS1 / HDAC inhibitor

References

[1] Fairfield H,Avery L.Multiple myeloma in the marrow: pathogenesis and treatments.Ann N Y Acad Sci2016;1364:32-51 PMCID:PMC4806534

[2] Barwick BG,Vertino PM.Cell of origin and genetic alterations in the pathogenesis of multiple myeloma.Front Immunol2019;10:1121 PMCID:PMC6558388

[3] Rajkumar SV.Multiple myeloma: 2020 update on diagnosis, risk-stratification and management.Am J Hematol2020;95:548-67

[4] Nadeem O,Anderson KC.Immunotherapeutic and targeted approaches in multiple myeloma.Immunotargets Ther2020;9:201-15 PMCID:PMC7569026

[5] Watanabe R,Kizaki M.Current approaches for the treatment of multiple myeloma.Int J Hematol2013;97:333-44

[6] Warburg O.The metabolism of carcinoma cells.J Cancer Res1925;9:148-63

[7] Liberti MV.The warburg effect: how does it benefit cancer cells?.Trends Biochem Sci2016;41:211-8 PMCID:PMC4783224

[8] Jin J,Choi YK.Targeting glutamine metabolism as a therapeutic strategy for cancer.Exp Mol Med2023;55:706-15 PMCID:PMC10167356

[9] Cruzat V,Noel Keane K,Newsholme P.Glutamine: metabolism and immune function, supplementation and clinical translation.Nutrients2018;10:1564 PMCID:PMC6266414

[10] Mohamed A,Khuri FR.Altered glutamine metabolism and therapeutic opportunities for lung cancer.Clin Lung Cancer2014;15:7-15 PMCID:PMC3970234

[11] Katt WP,Cerione RA.A tale of two glutaminases: homologous enzymes with distinct roles in tumorigenesis.Future Med Chem2017;9:223-43 PMCID:PMC5558546

[12] Chen L.Targeting glutamine induces apoptosis: a cancer therapy approach.Int J Mol Sci2015;16:22830-55 PMCID:PMC4613338

[13] Tzogani K,Walsh I.EMA review of panobinostat (farydak) for the treatment of adult patients with relapsed and/or refractory multiple myeloma.Oncologist2018;23:631-6 PMCID:PMC5947444

[14] Seto E.Erasers of histone acetylation: the histone deacetylase enzymes.Cold Spring Harb Perspect Biol2014;6:a018713 PMCID:PMC3970420

[15] Karagiannis D,Li A.Metabolic reprogramming by histone deacetylase inhibition preferentially targets NRF2-activated tumors.Cell Rep2024;43:113629 PMCID:PMC10853943

[16] Ri M,Nakashima T.Bortezomib-resistant myeloma cell lines: a role for mutated PSMB5 in preventing the accumulation of unfolded proteins and fatal ER stress.Leukemia2010;24:1506-12

[17] McNee G,Wei W.Citrullination of histone H3 drives IL-6 production by bone marrow mesenchymal stem cells in MGUS and multiple myeloma.Leukemia2017;31:373-81 PMCID:PMC5292682

[18] Okabe S,Gotoh A.Targeting phosphoinositide 3-kinases and histone deacetylases in multiple myeloma.Exp Hematol Oncol2021;10:19 PMCID:PMC7934550

[19] Okabe S,Moriyama M.WEE1 and PARP-1 play critical roles in myelodysplastic syndrome and acute myeloid leukemia treatment.Cancer Cell Int2023;23:128 PMCID:PMC10304360

[20] Buczkowska J.Two faces of glutaminase GLS2 in carcinogenesis.Cancers2023;15:5566 PMCID:PMC10705333

[21] Ying M,Zhu X,Zeng S.Lactate and glutamine support NADPH generation in cancer cells under glucose deprived conditions.Redox Biol2021;46:102065 PMCID:PMC8321918

[22] Qiu Q,Yang L.Targeting glutaminase1 and synergizing with clinical drugs achieved more promising antitumor activity on multiple myeloma.Oncotarget2019;10:5993-6005 PMCID:PMC6800263

[23] Richardson PG,Lonial S.Panobinostat: a novel pan-deacetylase inhibitor for the treatment of relapsed or relapsed and refractory multiple myeloma.Expert Rev Anticancer Ther2015;15:737-48

[24] Chou TC.Drug combination studies and their synergy quantification using the Chou-Talalay method.Cancer Res2010;70:440-6

[25] Jin L,Kang S.Glutaminolysis as a target for cancer therapy.Oncogene2016;35:3619-25 PMCID:PMC5225500

[26] Liao J,Hou G.Regulation of stem-like cancer cells by glutamine through β-catenin pathway mediated by redox signaling.Mol Cancer2017;16:51 PMCID:PMC5331650

[27] Johnsen HE,Schmitz A.The myeloma stem cell concept, revisited: from phenomenology to operational terms.Haematologica2016;101:1451-9 PMCID:PMC5479618

[28] Zaal EA,Oudaert I.Targeting coenzyme Q10 synthesis overcomes bortezomib resistance in multiple myeloma.Mol Omics2022;18:19-30

[29] Cea M,Gobbi M.New insights into the treatment of multiple myeloma with histone deacetylase inhibitors.Curr Pharm Design2013;19:734-44

[30] Vogl DT,Stewart K.Phase 1 study of CB-839, a first-in-class, glutaminase inhibitor in patients with multiple myeloma and lymphoma.Blood2015;126:3059

[31] Li C,Wang W.Targeting glutaminolysis to treat multiple myeloma: an in vitro evaluation of glutaminase inhibitors telaglenastat and epigallocatechin-3-gallate.Anticancer Agents Med Chem2023;23:779-85

[32] Effenberger M,Kunz V.Glutaminase inhibition in multiple myeloma induces apoptosis via MYC degradation.Oncotarget2017;8:85858-67 PMCID:PMC5689652

[33] Laubach JP,San-Miguel JF.Panobinostat for the treatment of multiple myeloma.Clin Cancer Res2015;21:4767-73

[34] Harding JJ,Munster P.A phase I dose-escalation and expansion study of telaglenastat in patients with advanced or metastatic solid tumors.Clin Cancer Res2021;27:4994-5003 PMCID:PMC9401498

[35] Riess JW,Shackelford D.Phase 1 trial of MLN0128 (Sapanisertib) and CB-839 HCl (Telaglenastat) in patients with advanced NSCLC (NCI 10327): rationale and study design.Clin Lung Cancer2021;22:67-70 PMCID:PMC7834952

[36] Zhao Y,Chen Y.5-Fluorouracil enhances the antitumor activity of the glutaminase inhibitor CB-839 against PIK3CA-mutant colorectal cancers.Cancer Res2020;80:4815-27 PMCID:PMC7642187

[37] García-Ortiz A,Encinas J.The role of tumor microenvironment in multiple myeloma development and progression.Cancers2021;13:217 PMCID:PMC7827690